title: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.
abstract: C-terminal brain (B-type) natriuretic peptide (BNP)-32 is a widely used clinical biomarker for the diagnosis, prognosis, and treatment of heart failure (HF). The 32-aa peptide is synthesized primarily in the atrial and ventricular myocardium and constitutes the mature biologically active form of immature BNP (pro-BNP). There has been mounting evidence that suggests BNP circulates in different structural forms that impact HF diagnosis and in vivo activity. Herein, we have developed and used an immunoaffinity purification assay to isolate endogenous BNP-32 from New York Heart Association class IV patient plasma for subsequent analysis by nano-liquid chromatography (LC) electrospray ionization Fourier transform ion cyclotron resonance (FT-ICR) MS. We have introduced stable isotope-labeled BNP-32 to the assayed plasma to enable quantification of endogenous levels of BNP-32. Unlike the chemically nonspecific point-of-care tests (POCTs) and RIAs used worldwide to quantify BNP-32 from plasma, FT-ICR-MS (unprecedented mass measurement accuracy) coupled with LC (retention time) affords extraordinary molecular specificity, and when combined with the use of internal standards is able to confidently identify and quantify BNP-32. The significance of this work is despite exceedingly high circulating levels of BNP-32 in the New York Heart Association class IV patients as determined by POCTs (>290 fmol/ml) nano-LC-electrospray ionization-FT-ICR-MS data did not reveal any endogenous BNP-32. These results provide molecularly specific evidence for the absence of circulating BNP-32 in advanced-stage HF patients and suggest the existence of altered forms of BNP that are contributing to the POCT values.
authors.affiliation: W. M. Keck FT-ICR Mass Spectrometry Laboratory and Mayo Proteomics Research Center, Division of Cardiovascular Diseases, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
authors.forename: Adam M
authors.initials: AM
authors.lastname: Hawkridge
authors.forename: Denise M
authors.initials: DM
authors.lastname: Heublein
authors.forename: H Robert
authors.initials: HR
authors.lastname: Bergen
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cataliotti
authors.forename: John C
authors.initials: JC
authors.lastname: Burnett
authors.forename: David C
authors.initials: DC
authors.lastname: Muddiman
mesh_terms: D002853:Chromatography, Liquid; D005260:Female; D006333:Heart Failure / Q000378:metabolism*; D006801:Humans; D007553:Isotope Labeling; D008297:Male; D013058:Mass Spectrometry; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000302:isolation & purification*
chemical_list: D020097:Natriuretic Peptide, Brain